Expresión y amplificación del gen HER2 en el cáncer gástrico avanzado
Date
2013
Type:
Artículo
item.page.extent
9
item.page.accessRights
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
Sociedad Médica de Santiago
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
Background: Overexpression/amplification of the HER2 gene in advanced gastric
cancer is a predictor of response to adjuvant therapy with monoclonal antibodies.
Aim: To determine the frequency of HER2 gene overexpression and amplification
in advanced gastric cancer. Material and Methods: One hundred nine advanced
gastric cancer biopsy specimens, from 76 men and 33 women aged 67 ± 14 and 62
± 12 years respectively, were selected. Three histological patterns (diffuse, intestinal
and mixed) were recognized. Automated immunohistochemistry was performed
with monoclonal c-erbB-2 (NCL-356) Novocastra. Fluorescent in situ hybridization
(FISH) for HER2 was performed in positive cases. Results: In 39% of cases,
immunohistochemical staining was negative. It was 1+, 2+ and 3+ positive in 15,
36 and 11% of cases, respectively. It was positive in 16% and 3% of intestinal type
and mixed carcinomas, respectively. It was negative in all diffuse carcinomas. FISH
was performed in 39 (2 +) cases and in 11 (3 +) cases. The gene amplification was
positive in two (2 +) and 11 (3 +) cases (11.9%). The overall concordance between
immunohistochemical staining and in situ hybridization was 85%. Conclusions: In
advanced gastric cancer, HER2 gene overexpression or amplification was observed in
11% and 12% of cases, respectively.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Revista Médica de Chile 2013, 141:1411-1419
Keywords
Gene amplification, HER2, protein, human, in situ hibridization, fluorescence, Immunohistochemistry